Beaird Harris Wealth Management LLC Makes New Investment in Twist Bioscience Co. (NASDAQ:TWST)

Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience Co. (NASDAQ:TWST) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,100 shares of the company’s stock, valued at approximately $95,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. raised its holdings in shares of Twist Bioscience by 3.4% during the third quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock valued at $11,756,000 after buying an additional 8,308 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the 3rd quarter valued at $34,000. Geode Capital Management LLC raised its stake in Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after acquiring an additional 26,145 shares in the last quarter. Barclays PLC boosted its position in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock worth $701,000 after purchasing an additional 4,169 shares in the last quarter.

Twist Bioscience Price Performance

TWST stock opened at $47.50 on Friday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -13.19 and a beta of 1.82. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company’s 50 day simple moving average is $44.94 and its 200-day simple moving average is $46.63.

Insider Activity

In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now owns 45,620 shares in the company, valued at approximately $2,034,652. This represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,216 shares of Twist Bioscience stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares of the company’s stock, valued at $35,557,638.60. This trade represents a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 101,787 shares of company stock worth $4,584,508 over the last quarter. Corporate insiders own 3.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TWST shares. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday. They issued an “outperform” rating and a $60.00 price objective for the company. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Scotiabank increased their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.